Drugs Made In America Acquisition Corp (DMAA) Stock Analysis

AI analysis of Drugs Made In America Acquisition Corp (DMAA)

Hold

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.

Valuation Metrics

The current forward P/E ratio for Drugs Made In America Acquisition Corp (DMAA) is 0.00, compared to its 5-year average forward P/E of 0.00.

Forward P/E

Strongly Undervalued

5Y Average P/E

0.00

Current P/E

0.00

Overvalued

0.00

Undervalued

0.00

Forward EV/EBITDA

Strongly Undervalued

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued

0.00

Undervalued

0.00

Forward P/S

Fair

5Y Average P/S

0.11

Current P/S

0.00

Overvalued

1.18

Undervalued

-0.96

Alphio AI Price Scenarios for DMAA

Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.

B

Bull

Bull · 25%DMAA

$10.91

Scenario price

B

Base

Base · 50%DMAA

$9.82

Scenario price

B

Bear

Bear · 25%DMAA

$9.57

Scenario price

Whales holding DMAA

G

Glazer Capital, LLC

+ HoldingDMAA

+3.19%

3M Return

W

Wolverine Asset Management, LLC

+ HoldingDMAA

-16.12%

3M Return

DMAA FAQ — answered by Alphio AI

Drugs Made In America Acquisition Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or other similar business combination with one or more businesses. The Company intends to focus its search for businesses in the pharmaceutical industry. The Company has neither engaged in any operations nor generated any revenues. It operates in the Financials sector.

Currently, DMAA is trading at $10.89, which is 97.5% of its 52-week high of $10.90. The RSI is at 59.42, indicating the asset is nearing overbought territory, which suggests caution. While the stock has shown a year-to-date change of +4.87%, the forward P/E is 0, indicating a lack of earnings growth expectations. The main risk is the current ratio of 0.02, suggesting potential liquidity issues.